Fidelity of Runx2 activity in breast cancer cells is required for the generation of metastases-associated osteolytic disease
- PMID: 15231660
- DOI: 10.1158/0008-5472.CAN-03-3851
Fidelity of Runx2 activity in breast cancer cells is required for the generation of metastases-associated osteolytic disease
Abstract
The osteolytic bone destruction associated with breast cancer skeletal metastases represents a serious and incurable clinical condition. However, the molecular mechanisms regulating tumor cell expression of factors involved in the generation of osteolytic disease remain elusive. We demonstrated recently that breast cancer cells express the Runx2 transcription factor, essential for bone formation and a regulator of skeletal homeostasis. Our experimental results demonstrate that perturbation of Runx2 regulatory function in tumor cells abolishes their ability to form osteolytic lesions in vivo. In vitro, we show that breast cancer cells inhibit osteoblast differentiation while concurrently enhancing osteoclast differentiation in marrow stromal cell cultures. Disruption of Runx2 activity abrogates both of these cancer cell-mediated effects on bone cells. These results demonstrate that Runx2 expression in breast cancer cells provides a molecular phenotype that enables the interactions between tumor cells and the bone microenvironment that lead to osteolytic disease.
Similar articles
-
Hypoxia and hypoxia-inducible factor-1 expression enhance osteolytic bone metastases of breast cancer.Cancer Res. 2007 May 1;67(9):4157-63. doi: 10.1158/0008-5472.CAN-06-2355. Cancer Res. 2007. PMID: 17483326
-
A role for Runx2 in normal mammary gland and breast cancer bone metastasis.J Cell Biochem. 2005 Oct 15;96(3):484-9. doi: 10.1002/jcb.20557. J Cell Biochem. 2005. PMID: 16052475 Review.
-
Nuclear factor-kappaB-dependent mechanisms in breast cancer cells regulate tumor burden and osteolysis in bone.Cancer Res. 2005 Apr 15;65(8):3209-17. doi: 10.1158/0008-5472.CAN-04-4017. Cancer Res. 2005. PMID: 15833852
-
Lack of noggin expression by cancer cells is a determinant of the osteoblast response in bone metastases.Am J Pathol. 2007 Jan;170(1):160-75. doi: 10.2353/ajpath.2007.051276. Am J Pathol. 2007. PMID: 17200191 Free PMC article.
-
Molecular mechanisms of tumor-bone interactions in osteolytic metastases.Crit Rev Eukaryot Gene Expr. 2000;10(2):159-78. Crit Rev Eukaryot Gene Expr. 2000. PMID: 11186331 Review.
Cited by
-
Integrin αvβ3 and CD44 pathways in metastatic prostate cancer cells support osteoclastogenesis via a Runx2/Smad 5/receptor activator of NF-κB ligand signaling axis.Mol Cancer. 2012 Sep 11;11:66. doi: 10.1186/1476-4598-11-66. Mol Cancer. 2012. PMID: 22966907 Free PMC article.
-
Ethanol Extract of Lycopus lucidus Turcz. ex Benth Inhibits Metastasis by Downregulation of Runx-2 in Mouse Colon Cancer Cells.Evid Based Complement Alternat Med. 2018 Jul 19;2018:9513290. doi: 10.1155/2018/9513290. eCollection 2018. Evid Based Complement Alternat Med. 2018. PMID: 30105080 Free PMC article.
-
A Molecular View of Pathological Microcalcification in Breast Cancer.J Mammary Gland Biol Neoplasia. 2016 Jun;21(1-2):25-40. doi: 10.1007/s10911-015-9349-9. Epub 2016 Jan 15. J Mammary Gland Biol Neoplasia. 2016. PMID: 26769216 Review.
-
RUNX2 correlates with subtype-specific breast cancer in a human tissue microarray, and ectopic expression of Runx2 perturbs differentiation in the mouse mammary gland.Dis Model Mech. 2014 May;7(5):525-34. doi: 10.1242/dmm.015040. Epub 2014 Mar 13. Dis Model Mech. 2014. PMID: 24626992 Free PMC article.
-
Exploring the transcriptional cooperation between RUNX2 and its associated elncRNA RAIN.Cell Death Dis. 2024 Sep 14;15(9):673. doi: 10.1038/s41419-024-07058-x. Cell Death Dis. 2024. PMID: 39271656 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical